Search Results 2001-2010 of 18787 for Relapse
"Currently there are six different CAR-T cell therapies approved for treatment of relapsed blood cancers. While the results are impressive, not everyone ...
participants should have had disease that has relapsed after or be refractory to intensive salvage chemotherapy, including autologous SCT. - PTCL-NOS ...
... Relapsed or Refractory Brain Tumors No Locations. This phase I trial studies the side effects and the best dose of wild-type reovirus (viral therapy) when ...
NYHA Class III heart failure • Must have experienced radiographic progression or relapse during or after 1L of EV and pembrolizumab. Participant who ...
"If I had one thing that I could tell all cancer patients, it would be that stress does not cause cancer. That is a common myth that causes a lot of unnecessary ...
Patients who previously responded to CNIs (CsA or tacrolimus), rituximab, or alkylating agents with either a CR or PR and subsequently relapsed are eligible ...
Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide-based haploidentical versus matched sibling donor reduced-intensity ...
documented relapse or progression on or after the most recent line of therapy 4. no standard therapy options likely to convey clinical benefit 2. Adequate ...
Patients who have developed an asymptomatic relapse as defined by: Cohort A: CA-125 ≥ 2 times ULN on 2 occasions at least 1 week apart (GCIG criteria) or ...
Treatment of relapsed or refractory peripheral T cell lymphoma. https://www.uptodate.com/contents/search. Accessed Dec. 30, 2025. Elsevier Point of Care ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.